Impact BioMedical
IBO
IBO was delisted on the 17th of November, 2026.
19 hedge funds and large institutions have $1.71M invested in Impact BioMedical in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
22% more capital inflows, than outflows
Capital inflows: $60.8K | Capital outflows: $50K
0.02% more ownership
Funds ownership: 3.56% → 3.58% (+0.02%)
5% less funds holding
Funds holding: 20 → 19 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$56.6K |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.17K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$638 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$240 |
| 5 |
Colonial Trust Advisors
Spartanburg,
South Carolina
|
+$41 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22.8K |
| 2 |
Jane Street
New York
|
-$11.3K |
| 3 |
Two Sigma Investments
New York
|
-$7.91K |
| 4 |
Mason & Associates (California)
Los Angeles,
California
|
-$4.6K |
| 5 |
BlackRock
New York
|
-$3.36K |
IBO Hedge Fund Activity: Q3 2026 in Review
19 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q3 2026, worth a combined $1.71M — down 3% from $1.76M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IBO and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Capital Management, adding an estimated $56.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $22.8K sold.
- 19 institutional investors held Impact BioMedical (IBO) as of Q3 2026, down from 20 in Q2 2026.
- Funds reported $1.71M of Impact BioMedical stock for Q3 2026, down 3% quarter-over-quarter.
- 4 funds opened new Impact BioMedical positions in Q3 2026 and 5 closed out, a net change of -1 holder.
- The largest Impact BioMedical buyer in Q3 2026 was Vanguard Capital Management, an estimated $56.6K added.
- The largest Impact BioMedical seller in Q3 2026 was Citadel Advisors, an estimated $22.8K sold.
Based on aggregated 13F filings for Q3 2026.